Skip to main content

Advertisement

SpringerLink
Log in

Self-limited acute hepatotoxicity caused by pegvisomant

  • Case Report
  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

We present a case of acute severe hepatitis in a patient with acromegaly receiving combination therapy with somatostatin analogs and pegvisomant. Hepatitis resolved completely 18 weeks after diagnosis of hypertransaminasemia without discontinuation of therapy and with a close clinical and biochemical follow-up. In this case, despite the severity of the hepatitis, therapy could be continued as hypertransaminasemia was gradually decreasing after the maximum peak. We also review the literature on toxic hepatitis associated to pegvisomant therapy analyzing the etiology, clinical predisposing factors and natural evolution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Melmed S (2006) Acromegaly. N Engl J Med 355:2558–2573. doi:10.1056/NEJMra062453

    Article  PubMed  CAS  Google Scholar 

  2. Stewart PM (2000) Current therapy for acromegaly. Trends Endocrinol Metab 11:128–132. doi:10.1016/S1043-2760(00)00244-7

    Article  PubMed  CAS  Google Scholar 

  3. Lancranjan I, Atkinson AB, Sandostatin LAR Group (1999) Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Pituitary 1:105–114. doi:10.1023/A:1009980404404

    Article  PubMed  CAS  Google Scholar 

  4. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Fried KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177. doi:10.1056/NEJM200004203421604

    Article  PubMed  CAS  Google Scholar 

  5. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Fried KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormon receptor antagonist. Lancet 358:1754–1759. doi:10.1016/S0140-6736(01)06844-1

    Article  PubMed  Google Scholar 

  6. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JAMJL, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644–1646. doi:10.1016/S0140-6736(05)63011-5

    Article  PubMed  CAS  Google Scholar 

  7. Shreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German pegvisomant observational study. Eur J Endocrinol 156:75–82. doi:10.1530/eje.1.02312

    Article  Google Scholar 

  8. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ (2006) Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154:213–220. doi:10.1530/eje.1.02079

    Article  PubMed  CAS  Google Scholar 

  9. Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ (2006) Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol 154:805–806. doi:10.1530/eje.1.02160

    Article  PubMed  CAS  Google Scholar 

  10. Lewis JH, Ahmed M, Shobassy A, Palese C (2006) Drug-induced liver disease. Curr Opin Gastroenterol 22:223–233. doi:10.1097/01.mog.0000218958.40441.fd

    Article  PubMed  Google Scholar 

  11. Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450–482. doi:10.1210/edrv-12-4-450

    Article  PubMed  CAS  Google Scholar 

  12. Petersenn S (2005) Efficacy and limits of somatostatin analogs. J Endocrinol Invest 28(Suppl International):53–57

    PubMed  CAS  Google Scholar 

  13. Plöckinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S (2008) Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab 93:1203–1210. doi:10.1210/jc.2007-1986

    Article  PubMed  Google Scholar 

  14. Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F (2006) Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 145(4):310–312

    PubMed  Google Scholar 

  15. Marazuela M, Dauden E, Ocón E, Moure D, Nattero L (2007) Pegvisomant-induced lipohypertrophy: report of a case with histopathology. Ann Intern Med 147(10):741–743

    PubMed  Google Scholar 

  16. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S (2008) Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 93(9):3515–3518. doi:10.1210/jc.2008-0833

    Article  PubMed  CAS  Google Scholar 

  17. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674. doi:10.1210/jc.2003-031199

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Nutrition, Instituto de Biomedicina de Sevilla (IBIS), Virgen del Rocio University Hospital, Manuel Siurot S/N Avenue, 41013, Seville, Spain

    A. Soto Moreno, R. Guerrero Vázquez, E. Venegas Moreno, S. Palma Milla & A. Leal Cerro

  2. Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain

    J. P. Castaño

Authors
  1. A. Soto Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Guerrero Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Venegas Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Palma Milla
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. P. Castaño
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Leal Cerro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Soto Moreno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Soto Moreno, A., Guerrero Vázquez, R., Venegas Moreno, E. et al. Self-limited acute hepatotoxicity caused by pegvisomant. Pituitary 14, 371–376 (2011). https://doi.org/10.1007/s11102-009-0173-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-009-0173-3

Keywords

Search

Navigation